This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (October 2008)

Levulan photodynamic therapy is a treatment method for certain skin conditions developed by DUSA Pharmaceuticals. The active ingredient is δ-aminolevulinic acid (ALA). Food and Drug Administration (FDA) approval for actinic keratosis was received in December 1999.

A 20% solution of ALA is applied to the lesions, and after 14–18 hours wait the skin is irradiated with blue light for 15 minutes. This generates an active form of oxygen in the skin that kills cells and bacteria. The treated areas are sensitive to light, and patients must protect themselves against bright sunshine for two or three days after treatment. Patients must stop using topical acne medicine and avoid steam rooms, hot showers, and generally protect the skin in every way possible for up to one week after treatment.

Contents 1 Acne 2 See also 3 External links 4 References

[edit] Acne

Levulan is also prescribed for the treatment of acne but this is an off-label use, which means it is not approved by the FDA.

On October 2008 Dusa Pharmaceuticals announced that it was no longer developing Levulan for the treatment of acne after the phase II results failed to show statistically significant results.^[1]

[edit] See also

• Photodynamic therapy
• Photomedicine

[edit] External links

• Prescription information
• Homepage of Dusapharma
• An individuals experience with Levulan treatment

[edit] References